ArticleNPJ precision oncology2025
Intratumoral plasma cells predict patient prognosis and responsiveness to neoadjuvant immunotherapy in advanced gastric cancer.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Tertiary lymphoid structures in neoadjuvant and perioperative cancer immunotherapy: a review and proposed framework for biomarker interpretation and validation.Frontiers in immunology · 2026Review
- The biological characteristics of tertiary lymphoid structures in head and neck cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Limited biomarker availability hinders the accurate prognostication of individual responses to immunotherapy in gastric cancer (GC). Mature tertiary lymphoid structures (mTLS) substantially affect immunotherapeutic efficacy in patients. However, the inherent limitations of tissue size in gastroscopic biopsies necessitate the development of a new mTLS marker-based classification strategy. An integrated analysis of multimodal data, including GC tissues collected from seven independent medical centers, single-cell transcriptomes, spatial transcriptomics, and transcriptome sequencing, revealed mTLS as a key site for somatic hypermutation and clonal selection in the infiltrating plasma cells of GC. An MZB1 positive score (MPS) was established based on the different degree of plasma cell infiltration between mTLS-positive (mTLS-Po) and mTLS-negative (mTLS-Ne) tumors characterizing MPS
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.